Recent developments in treatments targeting castration-resistant prostate cancer bone metastases.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Annals of Oncology

• Publication date

  2012-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdr573PMID 32018562
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC).

  2011cited by this paper
• Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

  2011cited by this paper
• National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010.

  2011cited by this paper
• Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

  2011cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011cited by this paper
• A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.

  2011cited by this paper
• Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC).

  2011cited by this paper
• Molecular remission in follicular lymphoma: is the era of residual disease monitoring over?

  2011cited by this paper
• Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223.

  2011cited by this paper
• [90Y]yttrium microspheres radioembolotherapy in desmoplastic small round cell tumor hepatic metastases.

  2011cited by this paper
• Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines

  2011cited by this paper
• The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo

  2010cited by this paper
• Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts

  2010cited by this paper
• Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer

  2010cited by this paper
• Bone-specific growth inhibition of prostate cancer metastasis by Atrasentan

  2010cited by this paper
• Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

  2010cited by this paper
• 668 A RANDOMIZED PHASE II STUDY OF IPILIMUMAB WITH ANDROGEN ABLATION COMPARED WITH ANDROGEN ABLATION ALONE IN PATIENTS WITH ADVANCED PROSTATE CANCER

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy

  2010cited by this paper
• Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.

  2010cited by this paper
• SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  2010cited by this paper
• Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

  2010cited by this paper
• Targeting the α Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis

  2010cited by this paper
• Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial

  2010cited by this paper
• SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis In vitro and In vivo through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis

  2010cited by this paper
• A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401.

  2010cited by this paper
• Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer

  2009cited by this paper
• Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

  2009cited by this paper
• Src kinases as therapeutic targets for cancer

  2009cited by this paper
• Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl‐2 protein level in hormone‐refractory prostate cancer cells

  2009cited by this paper
• Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer

  2009cited by this paper
• Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles

  2009cited by this paper
• Targeting Src signaling in metastatic bone disease

  2009cited by this paper
• Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054

  2009cited by this paper
• The Src Inhibitor AZD0530 Reversibly Inhibits the Formation and Activity of Human Osteoclasts

  2009cited by this paper
• Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis

  2009cited by this paper
• Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

  2009cited by this paper
• Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

  2009cited by this paper
• A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study

  2009cited by this paper
• Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.

  2009cited by this paper
• Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells.

  2009cited by this paper
• Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation

  2009cited by this paper
• SPECIFIC ENDOTHELIN‐A RECEPTOR ANTAGONISM FOR THE TREATMENT OF ADVANCED PROSTATE CANCER

  2009cited by this paper
• Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

  2009cited by this paper
• Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice

  2008cited by this paper
• Bisphosphonates: mechanism of action and role in clinical practice.

  2008cited by this paper
• Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530

  2008cited by this paper
• Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.

  2008cited by this paper
• Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

  2008cited by this paper
• Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.

  2008cited by this paper
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

  2008cited by this paper
• A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer

  2008cited by this paper
• Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor

  2008cited by this paper
• Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.

  2008cited by this paper
• Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer.

  2008cited by this paper
• Antitumor effects of bisphosphonates: promising preclinical evidence.

  2008cited by this paper
• Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

  2008cited by this paper
• Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.

  2008cited by this paper
• Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.

  2008cited by this paper
• Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer

  2008cited by this paper
• The cost of treating skeletal-related events in patients with prostate cancer.

  2008cited by this paper
• Thalidomide and lenalidomide: Mechanism-based potential drug combinations

  2008cited by this paper
• Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.

  2008cited by this paper
• In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer.

  2007cited by this paper
• Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.

  2007cited by this paper
• A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer

  2007cited by this paper
• The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer

  2007cited by this paper
• A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

  2007cited by this paper
• The role of Src in prostate cancer.

  2007cited by this paper
• Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

  2007cited by this paper
• Estimates of the cancer incidence and mortality in Europe in 2006.

  2006cited by this paper
• Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases

  2006cited by this paper
• Targeting Bone Metastasis in Prostate Cancer with Endothelin Receptor Antagonists

  2006cited by this paper
• The Bisphosphonate Olpadronate Inhibits Skeletal Prostate Cancer Progression in a Green Fluorescent Protein Nude Mouse Model

  2006cited by this paper
• Endothelin receptor A blockade enhances taxane effects in prostate cancer.

  2006cited by this paper
• Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment

  2006cited by this paper
• A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell–microenvironment interactions

  2005cited by this paper
• Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.

  2005cited by this paper
• Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.

  2005cited by this paper
• Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.

  2005cited by this paper
• Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid

  2005cited by this paper
• Osteoblasts in prostate cancer metastasis to bone

  2005cited by this paper
• Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.

  2005cited by this paper
• c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

  2005cited by this paper
• Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.

  2005cited by this paper
• Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

  2004cited by this paper
• Journal of Translational Medicine BioMed Central Review Endothelin receptors as novel targets in tumor therapy

  2004cited by this paper
• Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer.

  2004cited by this paper
• The role of bisphosphonates in breast and prostate cancers.

  2004cited by this paper
• Vascular Endothelial Growth Factor Contributes to the Prostate Cancer-Induced Osteoblast Differentiation Mediated by Bone Morphogenetic Protein

  2004cited by this paper
• Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.

  2004cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Bisphosphonates: clinical experience.

  2004cited by this paper
• Prostate cancer bone metastases promote both osteolytic and osteoblastic activity

  2004cited by this paper
• Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation

  2004cited by this paper
• Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.

  2004cited by this paper

• The Circulating miR-107 as a Potential Biomarker Up-Regulated in Castration-Resistant Prostate Cancer

  2024influential citation
• Revolutionizing of Bioactive Natural Products in Prostate Cancer Research and Care: Promising Discoveries and Future Directions

  2024cites this paper
• Biological Activity of Natural and Synthetic Peptides as Anticancer Agents

  2024cites this paper
• New Therapeutic Perspectives in Prostate Cancer: Patient-Derived Organoids and Patient-Derived Xenograft Models in Precision Medicine

  2023cites this paper
• Tumor suppressive miR-99b-5p as an epigenomic regulator mediating mTOR/AR/SMARCD1 signaling axis in aggressive prostate cancer

  2023cites this paper
• MicroRNA-99b-5p targets mTOR/AR axis, induces autophagy and inhibits prostate cancer cell proliferation.

  2022cites this paper
• MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer

  2021cites this paper
• Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer

  2021cites this paper
• MicroRNA miR-99b-5p Targets mTOR/AR axis, Induces Autophagy, and Inhibits Prostate Cancer Cell Proliferation

  2021cites this paper
• The Role of miR-107 in Prostate Cancer: A Review and Experimental Evidence

  2021cites this paper
• miRNA-128 modulates bone neoplasms cells proliferation and migration through the WNT/β-catenin and EMT signal pathways

  2021cites this paper
• Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

  2017cites this paper
• The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience

  2017cites this paper
• Metformin: A potential chemosensitizing agent for improving castration-resistant prostate cancer treatment

  2016cites this paper
• Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.

  2016cites this paper
• Gene expression profile of FVII and AR in primary prostate cancer

  2016cites this paper
• The comparative evaluation of apoptosis produced by leuprolide or orchiectomy on rat prostate tissue.

  2016cites this paper
• Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.

  2015cites this paper
• Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer.

  2015influential citation
• Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging

  2015cites this paper
• Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options.

  2014cites this paper
• Update in Systemic Therapy of Urologic Malignancies

  2014cites this paper
• Immunosuppressed Microenvironment – An Emerging Target in Prostate Cancer Management

  2014cites this paper
• Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options☆

  2014cites this paper
• Functional benefits are sustained after a program of supervised resistance exercise in cancer patients with bone metastases: longitudinal results of a pilot study

  2014cites this paper
• Quantitative assessment of quality of life in New Zealand prostate cancer survivors: the effect of androgen deprivation therapy

  2013cites this paper
• Nonhormone therapy for metastatic castration-resistant prostate cancer: chemotherapy, bone-targeted treatments, and others.

  2013cites this paper
• Current World Literature

  2013cites this paper
• Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.

  2013cites this paper
• Skeletal metastasis: treatments, mouse models, and the Wnt signaling

  2013cites this paper
• Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

  2013cites this paper
• Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis

  2013cites this paper
• Targeting the RANKL pathway: putting the brakes on prostate cancer progression in bone.

  2013cites this paper
• Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate

  2013cites this paper
• Novel and bone-targeted agents for CRPC.

  2012cites this paper
• Green Tea Polyphenols Induce p53-Dependent and p53-Independent Apoptosis in Prostate Cancer Cells through Two Distinct Mechanisms

  2012influential citation
• World Journal of Clinical Cancer Research

  year unknowncites this paper